Paul Marks (scientist)
Appearance
Paul Marks | |
---|---|
Born | |
Died | April 28, 2020 Manhattan, New York City, NY, U.S. | (aged 93)
Alma mater |
|
Known for | Paul Marks Prize for Cancer Research |
Children | Andrew Marks Matthew Marks Elizabeth Ostrer |
Scientific career | |
Institutions |
Paul Alan Marks (August 16, 1926 – April 28, 2020) was a medical doctor, researcher and administrator. He was a faculty member and president at Memorial Sloan Kettering Cancer Center.[1][2]
Background
Marks was born in
Institut Pasteur in France, he joined the faculty at Columbia University. Marks served as dean of the Medical Faculty at Columbia University from 1970 to 1973.[4] He was president and chief executive officer at Memorial Sloan Kettering from 1980 until 1999.[4] Marks died at his Manhattan home from pulmonary fibrosis and lung cancer on April 28, 2020, at the age of 93. [3]
Scholarly activities
Marks contributed to the fields of
HDAC inhibitors or HDIs). Marks and others found that drugs such as Trichostatin A and SAHA (vorinostat) can serve as anticancer agents.[5]
Marks published more than 400 scientific articles and was the editor-in-chief of journals including the Journal of Clinical Investigation and Blood.[6]
Honors and affiliations
- Member, National Academy of Sciences[4]
- Member, Institute of Medicine[4]
- Recipient, President's National Medal of Science[6]
- Fellow, American Academy of Arts and Sciences[4]
- Fellow, The American Philosophical Society[6]
Paul Marks Prize for Cancer Research
The Paul Marks Prize for Cancer Research was established by Memorial Sloan Kettering to honor Marks's contributions "as a distinguished scientist and leader".[4] The prize has been awarded every two years since 2001.
Works
References
- ^ Memorial Sloan Kettering Cancer Center biography
- ^ Businessweek profile[dead link ]
- ^ a b Schwartz, John (May 5, 2020). "Paul Marks, Who Brought Sloan Kettering to Greatness, Dies at 93". The New York Times. Retrieved May 5, 2020.
- ^ a b c d e f g MSKCC Paul Marks Prize website
- S2CID 12656582.
- ^ a b c PTC Therapeutics Archived 2014-10-02 at the Wayback Machine